Our meta‐ analysis showed beneficial effects  of statin use  on reducing inflammatory markers in patients with MetS and related disorders
& NA ; Current evidence suggests that statin use decreases the incidence of cardiovascular diseases ( CVD ) through reducing LDL cholesterol and decreasing inflammation .
Metabolic syndrome ( MetS ) is usually associated with increased inflammatory markers and increased risk of CVD .
Long-term statin therapy in patients with systolic heart failure and normal cholesterol: effects on elevated serum markers of collagen turnover, inflammation, and B-type natriuretic peptide.
BACKGROUND The role of statin therapy in heart failure ( HF ) is unclear . The amino-terminal propeptide of procollagen type III ( PIIINP ) predicts outcome in HF , and yet there are conflicting reports of statin therapy effects on PIIINP . OBJECTIVES This study determined whether there was an increase in serum markers of inflammation , fibrosis ( including PIIINP ) , and B-type natriuretic peptide ( BNP ) in patients with systolic HF and normal total cholesterol and determined the effects of long-term treatment with atorvastatin on these markers . METHODS Fifty-six white patients with systolic HF and normal cholesterol levels ( age 72 [ 13 ] years ; 68 % male ; body mass index 27.0 [ 7.3 ] kg/m(2 ) ; ejection fraction 35 [13]% ; 46 % with history of smoking ) were r and omly allocated to atorvastatin treatment for 6 months , titrated to 40 mg/d ( A group ) or not ( C group ) . Age- and /or sex-matched subjects without HF ( N group ) were also recruited . Biomarkers were measured at baseline ( all groups ) and 6 months ( A and C groups ) . RESULTS Serum markers of collagen turnover , inflammation , and BNP were significantly elevated in HF patients compared with normal participants ( all P < 0.05 ) . There were correlations between these markers in HF patients but not in normal subjects . Atorvastatin treatment for 6 months caused a significant reduction in the following biomarkers compared with baseline : BNP , from median ( interquartile range ) 268 ( 190 - 441 ) pg/mL to 185 ( 144 - 344 ) pg/mL ; high-sensitivity C-reactive protein ( hs-CRP ) , from 5.26 ( 1.95 -9.29 ) mg/L to 3.70 ( 2.34 - 6.81 ) mg/L ; and PIIINP , from 4.65 ( 1.86 ) to 4.09 ( 1.25 ) pg/mL ( all P < 0.05 baseline vs 6 months ) . Between-group differences were significant for PIIINP only ( P = 0.027 ) . There was a positive interaction between atorvastatin effects and baseline hs-CRP and PIIINP ( P < 0.01 ) . CONCLUSIONS Long-term statin therapy reduced PIIINP in this small , selected HF population with elevated baseline levels . Further evaluation of statin therapy in the management of HF patients with elevated PIIINP is warranted
Our meta‐ analysis showed beneficial effects  of statin use  on reducing inflammatory markers in patients with MetS and related disorders
& NA ; Current evidence suggests that statin use decreases the incidence of cardiovascular diseases ( CVD ) through reducing LDL cholesterol and decreasing inflammation .
Metabolic syndrome ( MetS ) is usually associated with increased inflammatory markers and increased risk of CVD .